| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology, Markers, Clinical Correlates |
Strojan2
midkrk
Departments of Radiotherapy [P. S., M. B.], Biochemistry [B. S., I. V.], and Tumor Biology [J. .], Institute of Oncology; University Department of Otorhinolaryngology and Cervicofacial Surgery [L. .]; Department of Biochemistry and Molecular Biology, Jo
ef Stefan Institute [J. K.], and KRKA, d.d., Research and Development Division, Department of Biochemical Research and Drug Design [J. K.], SI-1000 Ljubljana, Slovenia
 |
ABSTRACT |
|---|
 Top ABSTRACT INTRODUCTIONPATIENTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
In the present group, significantly higher concentrations of Cat B (P < 0.0001), Cat L (P < 0.0001) and Stef A (P = 0.006) were found in tumors compared with concentrations in their normal tissue counterparts. Cat concentrations in normal laryngeal tissue were significantly/marginally elevated compared with nonlaryngeal tissue (Cat B, P = 0.02; Cat L, P = 0.06). The tumor concentration of Cat L was found to correlate with pT classification (P = 0.005) and tumor-node-metastasis stage (P = 0.05), whereas the concentrations of Stefs A and B correlated with pN classification (P = 0.007 and P = 0.03, respectively) and tumor-node-metastasis stage of the disease (P = 0.02 and P = 0.03, respectively). There was no statistically significant difference between low and high Cat B or Cat L groups, regarding either disease-free survival or disease-specific survival, using a minimum P approach to determine cutoff concentrations. The risk of disease recurrence and SCCHN-related death was significantly higher in patients with low Stef A (P = 0.0006 and P = 0.0005, respectively) and Stef B (P = 0.0009 and P = 0.0007, respectively) tumors, compared with those with high-Stef A and Stef B tumors. These results remained significant even after Ps were adjusted for a possible bias in the estimated effect on survival. The survival analysis in the reference group also confirmed these findings (Stef A: P = 0.0009 and P = 0.002, respectively; Stef B: P = 0.03 and P = 0.009, respectively). To avoid any possible bias arising from the differences between the laboratories that performed the biochemical analysis, the concentrations of both Stefs in the present group and in the reference group were standardized and coupled together to form a uniform group. In univariate survival analysis, standardized values of Stef A and Stef B correlated inversely with the rate of relapse (P = 0.0000) and mortality rate (P = 0.0000). Multivariate regression analysis showed that the standardized value of Stef A is the strongest independent prognostic factor for both disease-free survival and disease-specific survival. These findings show the specific role of Cats B and L and Stefs A and B in the invasive behavior of SCCHN. Furthermore, Stef A proved to be a reliable prognosticator of the risk of relapse and death in patients with this type of cancer.
|
INTRODUCTION |
|---|
|
TopABSTRACTINTRODUCTIONPATIENTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Under certain conditions the Cats are secreted from cells, mainly as inactive precursors that require activation by another protease (3) . It has been proposed that extracellular Cats B and L, together with the members of other classes of proteinases, i.e., Cat D, palsminogen activators, and matrix metalloproteinases, are all subject to a cascade-like manner of activation. Because of altered or compromised regulation of the cascade response in tumor tissue, enzyme activation results in uncontrolled proteolysis of the extracellular matrix components, i.e., laminin, fibronectin, and type IV collagen, which is believed to be a preliminary condition for local and metastatic tumor spread (3) .
Active serine protease uPA plays a pivotal role in the cascade. It converts proenzyme plasminogen into the fibrinolytic peptide plasmin, which is capable of degrading most extracellular proteins either directly or indirectly through activation of other proteinases (4) . Activation of the precursor form of uPA into the enzymatically active uPA results from the proteolytic activity of Cats B and L (5 , 6) , and, vice versa, pro-Cat B can be activated by uPA (7) . As it was shown in vitro, the activation of both Cats is presumably caused by proteolytic action of aspartic protease Cat D (8) , although it has been reported that the processing of pro-Cats B and L to active enzymes can also be an autocatalytic process (9 , 10) . With its ability to be autoactivated in an acid microenvironment, Cat D adopts the role of initiator of the proteolytic cascade (11) . All of the three Cats—B, L, and D—can also directly degrade extracellular matrix proteins (12, 13, 14) .
A large body of literature has accumulated to suggest that cysteine proteinases and Stefs are involved in tumor invasion and metastasis. Alterations in the expression at mRNA and protein levels, as well as in the activity and trafficking of enzyme and inhibitor molecules, have been found to correlate with malignancy of various murine and human tumors (3) . In clinical studies of malignant melanoma (15) and breast (16, 17, 18, 19, 20, 21) , colorectal (22 , 23) , lung (24, 25, 26, 27) , gastric (28) , and brain (29) cancers, overexpression of Cats B and L, imbalance of the Cat:inhibitor ratio, or decreased total inhibitor activity have all been shown to be related to survival probability.
Cysteine proteinases and their endogenous inhibitors in SCCHN have
seldom been studied. The prognostic value of these enzymes and
inhibitors have been evaluated in four of seven published papers
on this topic (Table 1
, Refs.
30, 31, 32, 33, 34, 35, 36
). Russo et al. (33)
reported better DFS in patients who had tumor:normal tissue ratio of
Cat B activity below or equal to one. The results published by our
group in 1996 (34)
found that a better prognosis
correlated with lower concentrations of Cat L in tumor tissue for both
DFS and DSS analysis. In the same study, high concentrations of Stef A
and Stef B proved to be strong indicators of the rate of relapse and
the duration of survival after treatment for SCCHN (34)
.
These results were reconfirmed by a subsequent analysis in a
subpopulation of patients with laryngeal cancer (35)
.
Recently, we found that low serum and tissue levels of the least
studied of cysteine proteinases, Cat H, correlated with both better DFS
and better DSS (36)
.
|
);
(b) the reported results warranted further evaluation;
(c) the test kits used for the biochemical analysis of Cats
B and L had been upgraded and had been used in several clinical studies
on malignant melanoma (15)
and breast (18
, 19)
, colorectal (23)
, and lung (26)
cancers. Modified assays assure more precise measurement of enzyme
concentrations and allow comparisons with values measured in other
tumor types. For a more relevant estimate of the prognostic
significance of the studied Cats and Stefs, the follow-up of the
patients from our previous study (hereafter, the "reference group";
Ref. 34
) was updated, and their survival results were
included in this report. |
PATIENTS AND METHODS |
|---|
|
TopABSTRACTINTRODUCTIONPATIENTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
. The International Union Against Cancer
TNM (37)
classification was used for tumor staging, and
the histopathological grade was defined according to WHO criteria
(38)
.
|
The median age of these patients was 60 years, with a range of 37–72 years, and all of them were eligible for follow-up. As of August 31, 1999, disease recurrence and/or distant dissemination was diagnosed in 12 patients, and 10 of the 12 died of disease-related causes. Ten other patients died from causes other than the treated malignant disease. The median follow-up time for patients alive at the last follow-up examination was 30 months, with a range of 24–40 months.
Tissue Extraction.
For biochemical analysis of Cats and Stefs, two tissue samples of
200–500 mg, representing matched pairs, were obtained from the tumor
and the adjacent normal tissue during surgery. Immediately after
removal, they were immersed in liquid nitrogen; fat and necrotic parts
of the tissue were carefully removed. Pulverization was performed on
the frozen tissue with a Mikro-Dismembranator (Braun, Melsungen,
Germany) for 60 s at a maximum power, and the resulting tissue
powder was suspended in extraction buffer consisting of 5
mM Na2HPO4, 1
mM monothioglycerol, and 10% v/v glycerol (pH 7.4). The
suspension was centrifuged for 45 min at 100,000 x
g to obtain the supernatant, i.e., cytosol, which
was divided into aliquots and stored at -70°C until use. Total
protein concentration in tissue cytosol was determined according to the
method of Bradford (39)
.
Assays for Cats B and L and Stefs A and B.
For quantitative analysis of Cats B and L and Stefs A and B in tissue
cytosols, commercially available modified specific ELISAs (sandwich
ELISAs, KRKA d.d., Novo mesto, Slovenia) were used, as developed
at Joef Stefan Institute, Ljubljana, Slovenia (40)
.
Human Cats B and L (2)
, and recombinant Stefs A and B
expressed in Escherichia coli (41)
, were
used for immunization of animals and as standards for assay calibration
curves. The linearity of ELISAs was tested by serial dilutions of
tissue cytosol samples to the levels encompassing the range of assays.
The measured values of diluted samples were subsequently compared with
the calibration values. For the determination and characteristics of
recovery and within-run and between-run coefficients of variance, see
Kos et al. (40)
The diluted tissue cytosol was added to wells of a microtiter plate that had been precoated with the corresponding capture anti-Cat/Stef Ab. After a 2 h-incubation at 37°C, the wells were washed and filled with detection anti-Cat/Stef Ab conjugated with HRP. After an additional 2-h incubation at 37°C, the peroxidase substrate 3,3,5,5-tetramethyl benzidine (Sigma Chemical Co., St. Louis, MO) was added in the presence of hydrogen peroxide. The amount of degraded substrate, as a measure of bound immunocomplexed Cat/Stef, was visualized by absorbency at 450 nm, using a microplate reader (Model 450, Bio-Rad, USA). The particular Cat/Stef concentration was calculated from the corresponding calibration curve and expressed in ng/mgp.
For Cat B ELISA, immobilized rabbit and HRP-conjugated sheep polyclonal anti-Cat B IgG were used as capture and detection Abs, respectively. Tumor samples in 1:100 dilution and normal samples in 1:10 dilution were used in the assay. The detection limit of the assay was 0.9 ng/ml sample.
For Cat L ELISA, immunoselective polyclonal sheep anti-Cat L IgG was used for immobilization and as an HRP-conjugated Ab for detection. Tumor samples were diluted to 1:4, and normal tissue samples were diluted to 1:2. The detection limit of the assay was 1.7 ng/ml.
For Stef A ELISA, monoclonal murine anti-Stef A Abs were used in the assay as capture Abs and as HRP-conjugated detection Abs. Tumor and normal tissue samples in 1:100 dilution were used. The detection limit of the assay was 1 ng/ml.
For Stef B ELISA, monoclonal murine anti-Stef B Abs were used for capture and as HRP-conjugated Abs for detection. Tumor and normal tissue samples in 1:100 dilution were used. The detection limit of the assay was 1 ng/ml.
The polyclonal Abs used for Cats B and L ELISA recognize precursor molecules, enzyme-inhibitor complexes, and mature forms of the enzymes. According to the manufacturer, ELISAs for Cat B and Cat L show no cross-reactivity. The monoclonal Abs used for Stefs A and B ELISA bind enzyme-inhibitor complexes and free antigens and exhibit no cross-reactivity between the Stefs.
Reference Group.
Forty-one patients (1 female, 40 males), aged 40–69 years
(median, 56 years) with primary SCCHN, diagnosed and treated between
June 1992 and August 1993, were eligible for survival analysis.
Treatment regimen, sampling and cytosol preparation were essentially
the same as described above. By March 31, 1999, 26 patients were dead;
14 from the disease and 12 from causes unrelated to the disease.
Disease recurrence/dissemination was diagnosed in 16 patients. Median
follow-up of those alive was 69 months, with a range of 58–75 months.
Concentrations of Cat B and both Stefs were determined in tissue
samples from all of the 41 patients, and that of Cat L from 23 of the
41 patients, using test kits from the same manufacturer as those used
in the present study. However, in the period between both studies, the
manufacturer modified the test kits for Cat B and Cat L to upgrade
their specificity potential by improving the stability and by using
different lots of standards and Abs.
For details on the therapy, tumor characteristics, and the results of biochemical and statistical analysis of the reference group see Budihna et al. (34) .
Statistical Analysis.
The results were analyzed using a PC computer and BMDP software
package (BMDP Statistical Software, Los Angeles, CA). All of the tests
were two-sided and the results were considered statistically
significant at a P of 0.05. The differences between the
median concentrations of Cats and Stefs in matched pairs of tumor and
normal tissue samples were determined by the Wilcoxon signed-rank test.
The Mann-Whitney U test was used to test the relationship
between the median values of the tumor tissue enzyme and inhibitor
concentrations in different groups of patients. The strength of the
association between individual Cat and Stef concentrations was tested
using the Spearman rank correlation
(rs).
The statistical assessment of patient survival was carried out using
the Kaplan-Meier product-limit method (42)
and log-rank
comparison to evaluate the differences between the survival curves
(43)
. The primary end points of survival analysis were DFS
and DSS; the latter was calculated by censoring disease-unrelated
deaths. In both types of cases, the survival times were calculated from
the date of surgery. Concentrations of each individual Cat/Stef were
dichotomized according to their optimal cutoff concentrations, which
were determined among the measured values using the criterion of
maximal difference in the survival rates between low and high Cat/Stef
groups (i.e., minimum P approach,
Pmin). Because this approach has
proved to be associated with a considerable inflation in type I error
rate, thus falsely claiming a factor to be prognostically relevant, all
of the Pmin values < 0.05 were
corrected according to the recommendation of Altman et al.
(44)
, using the following formula:
 |
ef Stefan Institute).
Thus, the measured concentrations (Xi)
were standardized using group-specific mean
(Xmean) and SD values according to the
following formula:
 |
The study protocol was approved by the Medical Ethics Committee at the Ministry of Health of the Republic of Slovenia, and all of the included patients gave their informed consent to voluntary participation in the study.
|
RESULTS |
|---|
|
TopABSTRACTINTRODUCTIONPATIENTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
. The concentrations of both studied
enzymes and Stef A were significantly higher in tumors than in their
normal counterparts (Cat B: 422 versus 85 ng/mgp,
P < 0.0001; Cat L: 12.7 versus 5.1 ng/mgp,
P < 0.0001; Stef A: 451 versus 294 ng/mgp,
P = 0.006); however, the concentration of Stef B was
not significantly higher (288 versus 268 ng/mgp,
P > 0.05).
|
. For Cat L, a
significant relationship was found with local tumor extent
(P = 0.005) and TNM stage of the disease
(P = 0.05). Tumor concentration of Stef A was
significantly related to nodal involvement (P = 0.007)
and TNM stage (P = 0.03), as was the case in Stef B
(P = 0.02 and P = 0.03, respectively).
Lower Stef concentrations were measured in tumor tissue from patients
with recurrent disease, compared with those without evidence of
recurrent disease during follow-up (Stef A, P = 0.01;
Stef B, P = 0.003). Among Cats and inhibitors, a
significant correlation has been found between Cat B and Cat L
(rs = 0.67, P <
0.0001), between Stef A and Stef B (rs
= 0.69, P < 0.0001) and between Cat L and Stef A
(rs = 150 0.32, P =
0.03).
Univariate Survival Analysis.
To allow visualization of the association of Cat B and Cat L with DFS
and DSS, enzyme concentrations were dichotomized according to the
Pmin approach. Although no
statistically significant difference was observed between low and high
Cat groups at any chosen cutoff value, a trend toward higher survival
probability was apparent for lower Cat L levels. No such trend was
determined for Cat B.
In the case of Stefs A and B, patients with lower tumor content of
either inhibitor showed a poorer prognosis. There was a trend toward
longer survival with increasing levels of Stef A and Stef B in the
analysis for both DFS and DSS (Table 3)
.
The maximal differences in the survival rates between low and high Stef
groups were calculated to be 303 ng/mgp for Stef A and 240 ng/mgp for
Stef B. Using these values as cutoff concentrations, 29% of the tumors
were classified as Stef A-low and 35% as Stef B-low. The differences
in DFS and DSS rates between low and high Stef groups were highly
significant for both inhibitors, as shown in Table 4
. After the correction of
Pmin as calculated by means of
log-rank test for a possible bias in the estimated effect on survival,
the corresponding values of Pcor for
Stef A were 0.02 and 0.02 (DFS and DSS, respectively), and for Stef B
0.03 and 0.02. The corresponding figures for the reference group are
also presented in Table 4
.
|
|
; Fig. 2
).
The optimal cutoff value for Stef B was the 37th percentile in the
group. Using this cutoff point to discriminate between low and high
Stef B tumors, we calculated Pmin of
0.02 and 0.03 for DFS and DSS, respectively, with corresponding RRs of
2.2 and 2.2 (Table 5
; Fig. 2
). None of the listed
Pmin values for Stef B turned out to
be statistically significant after applying the correction formula
(DFS, Pcor = 0.37; DSS,
Pcor = 0.46).
|
|
, only Stef A and extracapsular
tumor spread were retained in the final model. |
DISCUSSION |
|---|
|
TopABSTRACTINTRODUCTIONPATIENTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
An important finding in the present study is that tumor levels of Stef A can reliably predict the clinical outcome of SCCHN, whereas the prognostic relevance of Stef B seems less clear than that of Stef A. In contrast to breast (16, 17, 18, 19, 20) , colorectal (22 , 23) , lung (24, 25, 26) , gastric (28) , and brain (29) cancer, Cat B and Cat L failed to demonstrate any predictive value in SCCHN.
Cats B and L.
In our study, significantly higher concentrations of both Cat B and Cat
L were found in the cytosols of tumors than in normal tissue, which
indicated that the invasive behavior of SCCHN is associated with the
action of cysteine proteinases. This same relationship between the Cat
B and Cat L activity levels observed in the sera of SCCHN patients
compared with that in healthy controls were reported by Kr
cicki
and Siewi
ski (31)
and by Bongers et al.
(32)
. A comparison between the present and the reference
group found that enzyme levels were three times lower in the present
group than in the reference group. However, in both groups, the ratio
of the median concentrations between tumor and normal tissue was of the
same magnitude [5.0 versus 5.0 for Cat B and 2.5
versus 1.7 for Cat L (Ref. 34
)], which
confirms the reliability of the observed differences between tumor and
normal tissue. A strong correlation has been found between individual
Cat B and Cat L tumor values, which suggests that both enzymes are
up-regulated in tumors in the same manner. On the other hand, only Cat
L and Stef A levels correlated significantly, which indicates a
difference in tumor-associated inhibition between both enzymes. In both
groups of patients, the present and the reference one, substantially
higher tumor and normal tissue concentrations of Cat B were measured
compared with Cat L. The same findings were reported in breast
(17, 18, 19)
, lung (26)
, and gastric
(28)
cancers. These data support the idea that the lower
expression of Cat L may be compensated for by a high rate of
effectiveness, particularly considering that both the activation
(18)
and the proteolytic activity of the enzyme (1
, 2)
resulted in at least a 10-times-faster degradation of protein
substrates than the other proteinases, including Cats B and H
(1)
.
In addition, we found that cytosols prepared from normal
laryngeal tissue samples contained higher concentrations of Cat B and
Cat L than cytosols from the oral cavity and pharynx. The same trend
was observed in the reference group (34)
. However, in the
cases of Cat D (48)
and uPA (49)
this
difference was also found to be statistically significant. The
absence of the difference in corresponding tumor concentrations of both
Cats between the groups could probably be explained by the fact that:
(a) the patients with laryngeal tumors experienced
significantly longer DFS and DSS (univariate analysis,
P = 0.03 and P = 0.05, respectively;
Table 5
); and (b) low Cat B and/or Cat L tumor/serum levels
or activity correlated with better survival probability of patients
with various tumor types (15
, 17, 18, 19, 20
, 22, 23, 24, 25, 26
, 28 , 29)
.
Consequently, the elevation of the enzyme concentrations in the
patients with laryngeal tumors may be less than in the nonlaryngeal
group, and the difference in the elevations results in the equalization
of their concentrations between the groups.
Furthermore, we observed that higher Cat L concentration was associated with advanced (T3 + 4 and SIII + IV) disease, as opposed to early (T1 + 2 and SI + II) disease. It could be speculated that the increased production and/or secretion of Cat molecules is a consequence of progressive dedifferentiation and/or destruction of cells and of changes in the malignant potential in tumors of a higher T stage and overall TNM stage. This is in agreement with the results obtained by Russo et al. (33) , who reported higher Cat B and L tumor activity to be associated with DNA aneuploid multiclonal (i.e., more malignant) tumors compared with DNA aneuploid monoclonal or diploid (i.e., less malignant) tumors. The trend in the differences in Cat tumor levels observed between the patients with and without disease recurrence in the present group and in the reference group (34) supports these findings.
Survival analysis in the reference group showed that patients with low tumor Cat L levels survived significantly longer than those with high enzyme levels. However, after correcting the Pmin as proposed by Altman et al. (44) , these differences lost their statistical significance. The results in the present group also deny the prognostic significance of Cat L, although the trend toward longer survival was also limited to lower levels of the enzyme. For Cat B, neither a significant difference nor a trend were observed in the studied groups. On the contrary, Russo et al. (33) reported the high tumor:mucosa ratio of Cat B activity to be significantly related to the risk of relapse in laryngeal cancer. In addition, longer survival probability was found to be related to a low tumor or serum concentration and/or activity levels of either Cats in patients with malignant melanoma (15) and breast (17, 18, 19, 20) , colorectal (22 , 23) , lung (24, 25, 26) , gastric (28) , and brain (29) cancer. The only exception is the study of Budihna et al. (16) , in which an inverse relationship between Cat B and prognosis in breast carcinoma was observed.
Because of the absence of other histologies among the above listed tumors [i.e., sarcoma, lymphoma, hepatocellular, transitional cell, and skin (excluding melanoma) carcinoma, hypernephroma, and so forth; Refs. 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 , 28 ], one could speculate that the prognostic relevance of Cats B and L might be determined by histological tumor type. However, a rather small incidence of some tumor types and/or small number of patients in certain studies, including ours, might be the reason for the false-negative results. In addition, different methods used for the detection of Cats, i.e., recognizing different forms of the enzymes, may also be a source of discrepancies when evaluating Cats’ prognostic role in various types of cancers. For example, Werle et al. (50) found only a fraction of Cat B active at a physiological pH of 7.5 to be of prognostic significance in squamous cell carcinoma of the human lung.
Stefs A and B.
We found that only Stef A, but not Stef B, concentration differed
significantly between tumor and normal tissue. However, it was not
changed to the extent as in Cat L and particularly in Cat B (1.5
versus 2.5 versus 5.2). Reports on cysteine
proteinase inhibitors are contradictory regarding their levels and/or
activity in malignant tissue compared with normal tissue
(3)
. These discrepancies could be attributed to different
causes of changed inhibitory capacity of Stefs associated with the
malignant transformation of cells, such as: (a) reduced or
insufficiently elevated Stef concentrations to efficiently compensate
for increased Cats (18)
; and (b) changes in the
molecular structure of Stefs without a change in their total
concentration, thereby decreasing their affinity for the targeted Cats
(51)
. The resulting imbalance between Cat and Stef
components of the proteolytic cascade is of critical importance for
tumor cell invasion after proteolytic degradation of extracellular
matrix components (18
, 25
, 52)
.
Moreover, a strong correlation has been found between Stef A and Stef B tumor concentrations, indicating that in individual tumors the expression of these two inhibitors is, to some extent, related. Comparing the concentrations of both Stefs, we have found that, in tumor and in normal tissue, Stef A content was approximately 1.6- and 1.1-fold, respectively, more than the content of Stef B. The corresponding numbers for the reference group were 1.7 and 1.5. The relationship between the levels of Stefs A and B found in malignant and normal tissue, which were both of squamous cell origin, is in accordance with the reported differences in the distribution of inhibitors among various tissues: the presence of Stef B in different tissues is relatively uniform, whereas Stef A is abundant primarily in various types of epithelial cells and in some cell types of the lymphoid tissue (2 , 3) .
In the present group, higher concentrations of both Stefs correlated significantly with less aggressive forms of disease, i.e., lower node (N0) and overall TNM stages (SI + II). In the reference group, on the other hand, a higher content of both Stefs was measured in advanced stages of disease (34) . Nevertheless, the protective role of the studied inhibitors found in the present study was also confirmed by the increased Stef A and Stef B concentrations in tumors of patients without recurrence of the disease. In addition, the results of univariate survival analysis in the present group and in the reference group showed that patients with Stef A or B concentration above the calculated cutoff concentrations do significantly better than those with a lower concentration of either inhibitor. The concept of the protective role of Stef A and Stef B is further supported by the survival results of Lah et al. (18) in breast carcinoma and by Knoch et al. (25) and Ebert et al. (27) in lung carcinoma. The only study that contradicts this assumption is that of Kuopio et al. (21) , in which the risk of breast-cancer-related deaths was found to be associated with Stef A-positive immunohistochemical staining of neoplastic cell subpopulations within the tumors. In contrast to the latter report, the type of analysis used in the above listed studies (18 , 25 , 27) , including ours (i.e., measurements from homogenized tumor tissue specimens), does not allow for differentiation between neoplastic and nonneoplastic cells to be the source of Stef A. Because of this difference, the opposing results of these studies should be interpreted with caution and require further evaluation.
The present study and that of Budihna et al. (i.e., the reference group; Ref. 34 ) are the first studies evaluating the prognostic value of these two inhibitors in SCCHN. The most important finding is that high levels of both Stefs in tumor tissue, and especially Stef A, predict longer survival of patients with this type of cancer. This statement is based on several facts: (a) in two independent groups, i.e., the present and the reference one, the probability of survival depended significantly on tumor Stefs concentrations; (b) even after applying the correction formula for Pmin, the differences in survival probability remained statistically significant for Stef A in both groups, and for Stef B in the present group; (c) in the case of Stef A, the optimal cutoff point was exactly the same in the present and the reference groups, i.e., the 29th percentile in both groups; (d) using the standardized values of inhibitor concentrations, both Stefs retained their prognostic significance at the calculated cutoff points, which for Stef A, was very close to that for the concentrations measured, i.e., the 30th percentile. In the case of Stef A, Pcor also reached the level of statistical significance; and (e) in multivariate analysis, the standardized values of Stef A turned out to be the most significant predictor of both the DFS and the DSS.
In conclusion, our data provide evidence that cysteine proteinases Cats B and L and their endogenous inhibitors Stefs A and B are implicated in the invasive behavior of SCCHN. In addition, higher tumor levels of both Stefs correlated significantly with longer survival probability in univariate survival analysis, and Stef A proved to be a reliable prognosticator in multivariate survival analysis. On the basis of the presented results, additional studies are required: (a) to evaluate the prognostic relevance of both Stefs—and that of Stef A in particular—in a more homogeneous and larger group of patients with SCCHN; and (b) to determine the value of their clinical applicability with respect to the selection of treatment in individual patients with this type of cancer.
|
FOOTNOTES |
|---|
1 Supported by the Ministry of Science and
Technology of Slovenia Grant J3–7952. 
2 To whom requests for reprints should be
addressed, at the Department of Radiotherapy, Institute of Oncology,
Zalo
ka 2, SI-1000, Slovenia. Phone: 386-61-1314225; Fax:
386-61-1314180; E-mail: pstrojan{at}onko-i.si
3 The abbreviations used are: Cat,
cathepsin; Stef, stefin; uPA, urokinase-type plasminogen activator;
SCCHN, squamous cell carcinoma of the head and neck; DFS, disease-free
survival; DSS, disease-specific survival; Ab, antibody; HRP,
horseradish peroxidase; RR, relative risk; CI, confidence interval;
TNM, tumor-node-metastasis (classification); mgp, mg of total protein;
Pmin, minimum P;
Pcor, corrected P; BMDP
Biomedical Data Processing.
Received 10/15/99; revised 12/13/99; accepted 12/21/99.
|
REFERENCES |
|---|
|
TopABSTRACTINTRODUCTIONPATIENTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
tabuc, B., Schweiger, A., Kraovec, M., Cimerman, N., Kopitar-Jerala, N., and Vrhovec, I. Cathepsins B, H, and L, and their inhibitors stefin A, and cystatin C in sera of melanoma patients. Clin. Cancer Res., 3: 1815–1822, 1997.
krk, J., Zakotnik, B., Gabrijel
i, D., and Lindtner, J. Prognostic value of total cathepsin B in invasive ductal carcinoma of the breast. Eur. J. Cancer, 31A: 661–664, 1995.
-Georgio S., Golouh R., Vrhovec I., Turk V. The expression of lysosomal proteinases and their inhibitors in breast cancer: possible relationship to prognosis of the disease. Pathol. Oncol. Res., 3: 89-99, 1997.[Medline]
ovec, M., Look, M. P., Cimerman, N., Meijer-van Gelder, M. E., Henzen-Logmans, S. C., van Putten, W. L. J., and Klijn, J. G. M. Prognostic significance of cathepsins B and L in primary human breast cancer. J. Clin. Oncol., 16: 1013–1021, 1998.
ovec M., Christensen I. J., Cimerman N., Stephens R. W., Brünner N. Prognostic value of cathepsin B and carcinoembryonic antigen in sera of patients with colorectal cancer. Clin. Cancer Res., 4: 1511-1516, 1998.[Abstract]
idanik B., Golouh R., Lah T. Cathepsin B immunohistochemical staining in tumor and endotelial cells is a new prognostic factor for survival in patients with brain tumors. Clin. Cancer Res., 5: 559-567, 1999.ski M., Krcicki T., Jarmu
owicz J., Berdowska I. Cysteine proteinase inhibitors in serum of patients with head and neck cancer. Diagn. Oncol., 2: 323-326, 1992.
cicki T., Siewiski M. Serum cathepsin B-like activity as a potential marker of laryngeal carcinoma. Eur. Arch. Oto-Rhino-Laryngol., 249: 293-295, 1992.[CrossRef][Medline]
mid, L., krk, J., Vrhovec, I., upevc, A., Rudolf, Z., argi, M., Kraovec, M., Svetic, B., Kopitar-Jerala, N., and Kos, J. Prognostic value of cathepsins B, H, L, D and their endogenous inhibitors stefins A and B in head and neck carcinoma. Biol. Chem. Hoppe-Seyler, 377: 385–390, 1996.
mid, L., Strojan, P., Budihna, M., krk, J., Vrhovec, J., argi, M., and Kos, J. Prognostic value of cathepsins B, L and stefins A and B in laryngeal carcinoma. Eur. Arch. Otolaryngol., 254: 150–153, 1997.
mid, L., Svetic, B., Vrhovec, I., Kos, J., and krk, J. Cathepsin H in squamous cell carcinoma of the head and neck. Radiol. Oncol., in press, 1999.
mid, A., Kraovec, M., Svetic, B., Lenari, B., Vrhovec, I., krk, J., and Turk, V. Lysosomal proteinases cathepsins D, B. H, L and their inhibitors stefins A and B in head and neck cancer. Biol. Chem. Hoppe-Seyler, 376: 401–405, 1995.
erovnik E., Lohner K., Turk V. Structural basis for the difference in thermodynamic properties between the two cysteine proteinase inhibitors human stefins A and B. Protein Eng., 7: 977-984, 1994.tnar S., 
ufer T., Rudolf Z. The urokinase-type plasminogen activator, its inhibitors and its receptor—the new prognostic factors in solid cancers. Radiol. Oncol., 31: 298-304, 1997.
mid, L., Vrhovec, I., and krk, J. Cathepsin D in tissue and serum of patients with squamous cell carcinoma of the head and neck. Cancer Lett., 130: 49–56, 1998.
mid, L., Vrhovec, I., and krk, J. Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) in tissue and serum of head and neck squamous cell carcinoma patients. Eur. J. Cancer, 34: 1193–1197, 1998.
ina M., Kastelic L., Kopitar-Jerala N., Turk V., Lah T. T. Cathepsin B and cysteine proteinase inhibitors in human lung cancer cell lines. Clin. Exp. Metastasis, 15: 368-381, 1997.[CrossRef][Medline]
This article has been cited by other articles:
|
|
 |
|
  T Leinonen, R Pirinen, J Bohm, R Johansson, A Rinne, E Weber, and V-M Kosma Biological and prognostic role of acid cysteine proteinase inhibitor (ACPI, cystatin A) in non-small-cell lung cancer J. Clin. Pathol., May 1, 2007; 60(5): 515 - 519. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
